In June 2020, we entered into an option and license agreement with AbbVie, which granted AbbVie the option to license worldwide rights to acazicolcept (ALPN-101), a first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology. During the option period, we will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for acazicolcept. Under the terms of the agreement, we received an upfront payment of $60 million and to date have received $45 million in pre-option development milestones. As a result of the December 2023 amendment, we will be eligible to receive up to an additional $501.25 million for exercise of the option and achievement of success-based development, regulatory, and commercial milestones. In addition, we are eligible to receive tiered royalties on net sales of acazicolcept.